Ketamine as a Potential Brain Enhancer?

Originally devised for surgical anesthesia in the 1960s, ketamine has become one of the most interesting and controversial compounds in neuroscience and psychiatry today [1]. Although traditionally used for anesthesia and pain control, over the last few decades, researchers and clinicians have revealed a spectrum of effects on the brain that encompass far more than just sedation. Among these are its potential to enhance brain function by modulating neuroplasticity [2] and cognition, as well as its suggested applications as a rapid-acting intervention for treatment-resistant psychiatric disorders [1,3-6].

To describe ketamine as a "brain enhancer" is both provocative and complex, given that its proposed benefits depend greatly on the dose, context, and the individual neurological status of the patient.

At sub-anesthetic doses, ketamine shows promise in improving neural adaptability, mood, and potentially cognitive performance in clinical populations.

This article explores how ketamine affects the brain, presents evidence for its role in cognitive enhancement, outlines the risks and benefits of its use, and highlights areas for future research.

What is Ketamine?

Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that promptly brings about anesthesia and analgesia. It interacts with other receptor systems, including opioid, muscarinic, and monoaminergic pathways, which contribute to its complex effects on the central nervous system [7].

The unique pharmacology of ketamine underpins both its therapeutic potential and its inherent risks. Originally used for anesthesia in clinical settings, such as battlefield medicine [8], it has since been repurposed for the treatment of psychiatric conditions such as treatment-resistant depression [9]. 

How Does Ketamine Work in the Brain?

Ketamine’s primary action is antagonism of NMDA receptors. These are key glutamate receptors involved in synaptic transmission and plasticity. By blocking NMDA receptors, ketamine disinhibits glutamatergic activity, resulting in increased glutamate release and downstream activation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors [10-12].

How Might Ketamine Enhance Brain Function?

One of the most compelling reasons ketamine is studied as a potential "brain enhancer" is its ability to augment neuroplasticity — the capacity of the brain to reorganize itself by forming new neural connections [2,13].

Studies in animal and cell models show enhanced synaptogenesis (formation of new synapses) and increased expression of proteins related to neural growth following ketamine administration [14,15].

These effects are especially pronounced in brain areas associated with mood, memory, and executive function (e.g., the prefrontal cortex and hippocampus). A rodent study of neurological injury treated with ketamine demonstrates increased dendritic branching and levels of plasticity-related proteins such as BDNF, suggesting structural neural recovery [15,16].

Ketamine’s rapid antidepressant effects are well documented. Patients receiving sub-anesthetic ketamine infusions can experience mood improvements within hours, which sits in stark contrast to the weeks usually required for standard antidepressants [17].

Improved mood and reduced symptoms of depression, anxiety, or PTSD can themselves lead to secondary cognitive enhancements. For example, improved attention, reduced mental fatigue, and increased motivation could all be interpreted as "enhanced brain function." However, these are indirect effects stemming from improved mental health rather than direct augmentation of cognitive capacity.

What Does the Evidence Say About Ketamine and Cognition?

The broader question about whether ketamine enhances cognition in healthy brains, rather than restoring or improving function in clinical populations, is a complex and nuanced picture.

Systematic evidence shows that ketamine often improves certain cognitive domains in individuals with depression.

Reviews report improvements in processing speed, working memory, verbal memory, and cognitive flexibility following ketamine treatment in major depressive disorder [18]. Other studies suggest ketamine may counter cognitive impairments associated with psychiatric conditions, possibly through its effects on synaptic connectivity and mood regulation [19].

In healthy populations, research on cognitive enhancement is scarce and more disjointed. Ketamine can acutely impair cognition at higher or recreational doses (e.g., dissociation), which contradicts the notion of it being a generalized brain enhancer [20]. Some neural modulation studies show changes in neural network dynamics and firing patterns under ketamine, but do not clearly translate to improved cognitive performance [21,22].

In short, while ketamine may create the neural conditions favorable for plasticity, the evidence that it "boosts" cognitive abilities in the brains of healthy people remains limited and inconclusive at present.

Mechanistic Synergy: How Ketamine Could Benefit Brain Function

Ketamine’s influence on neuroplasticity and cognition appears to involve the interplay between several molecular and cellular processes. These comprise increased glutamate release, a boost in BDNF and synaptic protein synthesis, and modulation of inhibitory neurotransmitters.

These mechanisms could "prime" the brain for enhanced adaptability, which is particularly useful in settings of recovery from illness or psychological restructuring.

Risks, Misconceptions, and Responsible Use of Ketamine

Ketamine is not a universal cognitive enhancer akin to a "smart drug" or nootropic. Its effects depend heavily on the dose and delivery method. Sub-anesthetic therapeutic doses differ drastically from recreational use.

As mentioned above, benefits are more consistently documented in clinical conditions with relation to depression, PTSD, or neurodegenerative risk, not in healthy people seeking cognitive enhancement. Therapeutic settings (with psychotherapy or cognitive interventions) also seem to produce the best outcomes.

Importantly, ketamine has substantial abuse potential and can cause hallucinations, dissociation, and altered perception at higher doses. When misused, it can result in cardiovascular changes, sedation, and respiratory effects, as well as long-term cognitive issues with frequent recreational use.

High-profile cases (overdose deaths associated with unsupervised use) reinforce the importance of medical oversight and caution in off-label applications [23-25].

Using ketamine purely for cognitive enhancement purposes raises some ethical concerns, regulatory challenges, and unknown long-term effects. Unlike targeted therapeutic use under professional supervision, off-label enhancement poses risks that likely outweigh the potential benefits [25].

Conclusion

Ketamine has earned its place as a neuroscience breakthrough and essential medicine. In clinical settings, particularly for depression and cognitive deficits tied to psychiatric conditions, ketamine therapy can lead to improvements in cognition, mood, and neural connectivity.

Its influence on glutamate systems, BDNF, and synaptogenesis gives it a unique mechanistic profile compared to conventional drugs. However, in healthy brains, evidence for cognitive enhancement remains preliminary and inconsistent at the moment.

References

[1]         A.T. Can, J. Lagopoulos, P.B. Fitzgerald, N.W. Bailey, M. Dutton, Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy, Aust N Z J Psychiatry (2025) 00048674251396009. https://doi.org/10.1177/00048674251396009.

[2]         L.R. Aleksandrova, A.G. Phillips, Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics, Trends in Pharmacological Sciences 42 (2021) 929–942. https://doi.org/10.1016/j.tips.2021.08.003.

[3]         K. Ryan, A. Hosanagar, Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions, Curr Psychiatry Rep 25 (2023) 337–344. https://doi.org/10.1007/s11920-023-01432-w.

[4]         A. Lengvenyte, E. Olié, P. Courtet, Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine’s Antisuicidal Actions, Curr Psychiatry Rep 21 (2019) 132. https://doi.org/10.1007/s11920-019-1108-y.

[5]         V.M. Juby, S. Paruk, M. Tomita, B. Chiliza, Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic, South African Journal of Psychiatry 30 (2024). https://doi.org/10.4102/sajpsychiatry.v30i0.2176.

[6]         B. Sachdeva, P. Sachdeva, S. Ghosh, F. Ahmad, J.K. Sinha, Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects, Ibrain 9 (2023) 90–101. https://doi.org/10.1002/ibra.12094.

[7]         G. Mion, T. Villevieille, Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings ), CNS Neurosci Ther 19 (2013) 370–380. https://doi.org/10.1111/cns.12099.

[8]         E. Leslie, E. Pittman, B. Drew, B. Walrath, Ketamine Use in Operation Enduring Freedom, Military Medicine 186 (2021) e720–e725. https://doi.org/10.1093/milmed/usab117.

[9]         G. Serafini, R. Howland, F. Rovedi, P. Girardi, M. Amore, The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review, CN 12 (2014) 444–461. https://doi.org/10.2174/1570159X12666140619204251.

[10]       D. Matveychuk, R.K. Thomas, J. Swainson, A. Khullar, M.-A. MacKay, G.B. Baker, S.M. Dursun, Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers, Therapeutic Advances in Psychopharmacology 10 (2020) 2045125320916657. https://doi.org/10.1177/2045125320916657.

[11]       B. Moghaddam, B. Adams, A. Verma, D. Daly, Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex, J. Neurosci. 17 (1997) 2921–2927. https://doi.org/10.1523/JNEUROSCI.17-08-02921.1997.

[12]       L.R. Aleksandrova, A.G. Phillips, Y.T. Wang, Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism, J Psychiatry Neurosci 42 (2017) 222–229. https://doi.org/10.1503/jpn.160175.

[13]       H. Wu, N.K. Savalia, A.C. Kwan, Ketamine for a Boost of Neural Plasticity: How, but Also When?, Biological Psychiatry 89 (2021) 1030–1032. https://doi.org/10.1016/j.biopsych.2021.03.014.

[14]       P.A. Zunszain, M.A. Horowitz, A. Cattaneo, M.M. Lupi, C.M. Pariante, Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties, Mol Psychiatry 18 (2013) 1236–1241. https://doi.org/10.1038/mp.2013.87.

[15]       N.I. Martínez-Torres, J. Cárdenas-Bedoya, B.M. Torres-Mendoza, Ketamine enhances neurological function through neuronal and plasticity-related protein changes in rats with permanent middle cerebral artery occlusion, Metab Brain Dis 40 (2025) 297. https://doi.org/10.1007/s11011-025-01725-4.

[16]       C. Björkholm, L.M. Monteggia, BDNF – a key transducer of antidepressant effects, Neuropharmacology 102 (2016) 72–79. https://doi.org/10.1016/j.neuropharm.2015.10.034.

[17]       M. Yavi, H. Lee, I.D. Henter, L.T. Park, C.A. Zarate, Ketamine treatment for depression: a review, Discov Ment Health 2 (2022) 9. https://doi.org/10.1007/s44192-022-00012-3.

[18]       B. Souza-Marques, C. Santos-Lima, L. Araújo-de-Freitas, F. Vieira, A.P. Jesus-Nunes, L.C. Quarantini, A.S. Sampaio, Neurocognitive Effects of Ketamine and Esketamine for Treatment-Resistant Major Depressive Disorder: A Systematic Review, Harv Rev Psychiatry 29 (2021) 340–350. https://doi.org/10.1097/HRP.0000000000000312.

[19]       K. Hashimoto, Arketamine for cognitive impairment in psychiatric disorders, Eur Arch Psychiatry Clin Neurosci 273 (2023) 1513–1525. https://doi.org/10.1007/s00406-023-01570-5.

[20]       M.T. Davis, N. DellaGiogia, P. Maruff, R.H. Pietrzak, I. Esterlis, Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder, Transl Psychiatry 11 (2021) 205. https://doi.org/10.1038/s41398-021-01327-5.

[21]       V. Bharmauria, H. Ramezanpour, A. Ouelhazi, Y. Yahia Belkacemi, O. Flouty, S. Molotchnikoff, KETAMINE: Neural- and network-level changes, Neuroscience 559 (2024) 188–198. https://doi.org/10.1016/j.neuroscience.2024.09.010.

[22]       A. Zavaliangos-Petropulu, S.M. McClintock, J. Khalil, S.H. Joshi, B. Taraku, N.B. Al-Sharif, R.T. Espinoza, K.L. Narr, Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression, Journal of Affective Disorders 333 (2023) 161–171. https://doi.org/10.1016/j.jad.2023.04.015.

[23]       T.V. Chaves, B. Wilffert, Z.M. Sanchez, Overdoses and deaths related to the use of ketamine and its analogues: a systematic review, The American Journal of Drug and Alcohol Abuse 49 (2023) 141–150. https://doi.org/10.1080/00952990.2022.2132506.

[24]       S. Sassano-Higgins, D. Baron, G. Juarez, N. Esmaili, M. Gold, A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine, Depress Anxiety 33 (2016) 718–727. https://doi.org/10.1002/da.22536.

[25]       K. Wolff, A.R. Winstock, Ketamine: From Medicine to Misuse, CNS Drugs 20 (2006) 199–218. https://doi.org/10.2165/00023210-200620030-00003.